Compare Stocks: EDSA, KROS, GALT, and GLSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDSA Edesa Biotech	$5.24 -0.6%	$6.38	$0.72 ▼ $20.32	$50.77M	1.09	60,728 shs	37,036 shs
GALT Galectin Therapeutics	$3.12 -9.6%	$3.53	$2.03 ▼ $7.13	$227.21M	0.41	540,705 shs	370,877 shs
GLSI Greenwich LifeSciences	$15.50 +7.9%	$19.16	$7.78 ▼ $34.10	$210.78M	1.46	169,170 shs	176,121 shs
KROS Keros Therapeutics	$10.69 -4.1%	$10.62	$9.69 ▼ $22.55	$221.07M	0.99	204,469 shs	170,834 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDSA Edesa Biotech	-0.57%	+0.19%	-25.25%	-60.51%	+147.17%
GALT Galectin Therapeutics	-9.57%	+2.97%	-23.15%	+38.67%	-24.82%
GLSI Greenwich LifeSciences	+7.94%	+14.48%	-21.72%	-37.27%	+27.26%
KROS Keros Therapeutics	-4.13%	+5.74%	-9.41%	-8.24%	-22.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDSA Edesa Biotech	$5.24 -0.6%	$6.38	$0.72 ▼ $20.32	$50.77M	1.09	60,728 shs	37,036 shs
GALT Galectin Therapeutics	$3.12 -9.6%	$3.53	$2.03 ▼ $7.13	$227.21M	0.41	540,705 shs	370,877 shs
GLSI Greenwich LifeSciences	$15.50 +7.9%	$19.16	$7.78 ▼ $34.10	$210.78M	1.46	169,170 shs	176,121 shs
KROS Keros Therapeutics	$10.69 -4.1%	$10.62	$9.69 ▼ $22.55	$221.07M	0.99	204,469 shs	170,834 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDSA Edesa Biotech	-0.57%	+0.19%	-25.25%	-60.51%	+147.17%
GALT Galectin Therapeutics	-9.57%	+2.97%	-23.15%	+38.67%	-24.82%
GLSI Greenwich LifeSciences	+7.94%	+14.48%	-21.72%	-37.27%	+27.26%
KROS Keros Therapeutics	-4.13%	+5.74%	-9.41%	-8.24%	-22.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	-4.58% Downside
GALT Galectin Therapeutics	1.67	Reduce	$11.00	252.56% Upside
GLSI Greenwich LifeSciences	2.33	Hold	$57.00	267.74% Upside
KROS Keros Therapeutics	2.22	Hold	$20.50	91.77% Upside

Current Analyst Ratings Breakdown

Latest EDSA, KROS, GALT, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/13/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/29/2026	EDSA Edesa Biotech	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/23/2026	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
6/18/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/15/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.45 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
KROS Keros Therapeutics	$244.06M	0.87	$4.35 per share	2.46	$15.51 per share	0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDSA Edesa Biotech	-$7.19M	-$1.34	N/A	N/A	N/A	N/A	-286.52%	-75.36%	8/14/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.41	N/A	N/A	N/A	N/A	N/A	-164.69%	8/13/2026 (Estimated)
GLSI Greenwich LifeSciences	-$19.36M	-$1.57	N/A	N/A	N/A	N/A	-941.15%	-368.53%	8/13/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	N/A

Latest EDSA, KROS, GALT, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	N/A	EDSA Edesa Biotech	-$0.4350	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	N/A	N/A	N/A	N/A	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A
5/15/2026	Q1 2026	GALT Galectin Therapeutics	-$0.06	-$0.08	-$0.02	-$0.08	N/A	N/A
5/14/2026	Q2 2026	EDSA Edesa Biotech	-$0.24	-$0.49	-$0.25	-$0.49	$0.05 million	N/A
5/14/2026	Q1 2026	KROS Keros Therapeutics	-$1.0229	-$1.21	-$0.1871	-$1.21	$1.93 million	$0.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDSA Edesa Biotech	N/A	4.76	4.76
GALT Galectin Therapeutics	N/A	2.15	2.15
GLSI Greenwich LifeSciences	N/A	2.01	2.01
KROS Keros Therapeutics	N/A	21.96	21.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDSA Edesa Biotech	5.50%
GALT Galectin Therapeutics	11.68%
GLSI Greenwich LifeSciences	4.16%
KROS Keros Therapeutics	71.56%

Insider Ownership

Company	Insider Ownership
EDSA Edesa Biotech	24.40%
GALT Galectin Therapeutics	52.60%
GLSI Greenwich LifeSciences	51.47%
KROS Keros Therapeutics	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDSA Edesa Biotech	20	9.63 million	7.28 million	Not Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable

EDSA, KROS, GALT, and GLSI Headlines

Recent News About These Companies

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages

August 10 at 2:15 AM | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

August 10 at 2:13 AM | marketbeat.com

Keros Therapeutics (NASDAQ:KROS) Rating Increased to Sell at Wall Street Zen

August 8 at 2:32 AM | americanbankingnews.com

Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen

August 8 at 1:59 AM | marketbeat.com

Equities Analysts Offer Predictions for KROS FY2026 Earnings

August 8 at 1:44 AM | americanbankingnews.com

Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS

August 7, 2026 | marketbeat.com

Wells Fargo Issues a Buy Rating on Keros Therapeutics (KROS)

August 6, 2026 | theglobeandmail.com

FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst

August 6, 2026 | marketbeat.com

Leerink Partners Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00

August 6, 2026 | americanbankingnews.com

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)

August 5, 2026 | theglobeandmail.com

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

August 4, 2026 | zacks.com

Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners

August 4, 2026 | marketbeat.com

Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS

August 3, 2026 | marketbeat.com

Keros Therapeutics Reports Second Quarter 2026 Financial Results

August 3, 2026 | globenewswire.com

Arrowstreet Capital Limited Partnership Sells 744,267 Shares of Keros Therapeutics, Inc. $KROS

August 3, 2026 | marketbeat.com

Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research

July 31, 2026 | marketbeat.com

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

July 30, 2026 | globenewswire.com

New Strong Sell Stocks for July 30th

July 30, 2026 | zacks.com

Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

Keros Therapeutics, Inc. annonce la nomination d'Annita Tanini au poste de responsable comptable par intérim, à compter du 4 août 2026

July 24, 2026 | zonebourse.comZ

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages

July 16, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA, KROS, GALT, and GLSI Company Descriptions

Edesa Biotech NASDAQ:EDSA

$5.24 -0.03 (-0.57%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$5.53 +0.29 (+5.52%)

As of 06:25 AM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Galectin Therapeutics NASDAQ:GALT

$3.12 -0.33 (-9.57%)

As of 08/10/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Greenwich LifeSciences NASDAQ:GLSI

$15.50 +1.14 (+7.94%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$16.08 +0.58 (+3.72%)

As of 07:00 AM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Keros Therapeutics NASDAQ:KROS

$10.69 -0.46 (-4.13%)

As of 08/10/2026 04:00 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDSA, KROS, GALT, and GLSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDSA, KROS, GALT, and GLSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDSA, KROS, GALT, and GLSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA, KROS, GALT, and GLSI Company Descriptions

Edesa Biotech NASDAQ:EDSA

Galectin Therapeutics NASDAQ:GALT

Greenwich LifeSciences NASDAQ:GLSI

Keros Therapeutics NASDAQ:KROS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDSA, KROS, GALT, and GLSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDSA, KROS, GALT, and GLSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDSA, KROS, GALT, and GLSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA, KROS, GALT, and GLSI Company Descriptions

Edesa Biotech NASDAQ:EDSA

Galectin Therapeutics NASDAQ:GALT

Greenwich LifeSciences NASDAQ:GLSI

Keros Therapeutics NASDAQ:KROS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools